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ALTERNATING REGIMEN HYPER CVAD + IMATINIB IN PH (+) ALL PA-
TIENT ON HIGH-FLUX DIALYSIS
Stelts, S.D.1, Butler, C.2, Goorha, S.2 1Methodist University Hospital,
Memphis, TN; 2University of Tennessee Cancer Institute, Memphis, TN
Lack of pharmacokinetic data on chemotherapy clearance in
high flux hemodialysis hinders safe and effective dosing. We pres-
ent a case of a 58 year old female diagnosed in September 2009
with Ph (+) ALL and a past medical history of focal segmental glo-
merular sclerosis on hemodialysis. The patient intially presented
with worsening renal function, fevers and peripheral blasts.
Upon diagnosis of Ph (+) ALL, the decision was made to treat
with Hyper CVAD, a regimen of hyper fractionated cyclophos-
phamide, doxorubicin, vincristine and dexamethasone (odd cycle)
alternating cycles with high dose methotrexate and high dose
cytarabine (even cycle). High flux hemodialysis is relatively new,
utilizing improved membranes that efficiently remove low molec-
ular weight solutes and that are more effective at removing
medium and high molecular weight solutes. Currently the dosing
recommendations for chemotherapy are based on low flux hemo-
dialysis. Weighing the potential for improved solute clearance and
manufacturer dosing recommendations, no dose adjustments were
made for the odd cycles of Hyper CVAD. Imatinib was started at
100 mg for cycle 1, titrated up to 200 mg by cycle 3 and increased
to 400 mg at completion without side effects. Methotrexate is
poorly removed by low flux hemodialysis and only one case report
in a single patient provides pharmacokinetic information on
removal by high flux hemodialysis. For even cycles of Hyper
CVAD the methotrexate was initially dosed at 200 mg/m2, deter-
mined by estimating a dose cleared by 1 high flux hemodialysis
session using the time averaged clearance reported in the case
report by Murashima and colleagues. The methotrexate was
adequately removed based on serum levels and patient tolerance.
The dosage was increased to 500 mg/m2 for subsequent cycles.
Further dose escalation was halted due to development of febrile
neutropenia requiring hospitalization. Cytarabine was dosed at
100 mg/m2 continuous infusion for cycle 1 and increased to 200
mg/m2 base on manufacturer recommendations. The patient tol-
erated 8 cycles of Hyper CVAD with minimal side effects and 2
admissions for neutropenic fever. Complete remission was docu-
mented in December 2009. She remained in remission for 4
months after completion in April 2009. Recently reinduced with
Hyper CVAD, peg asparaginase, and dasatinib with documented
molecular remission.555
DRUG-DRUG INTERACTION BETWEEN TACROLIMUS AND AZOLE ANTI-
FUNGAL AGENTS, ITRACONAZOLE AND VORICONAZOLE, IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Udagawa, R.1, Koido, K.1, Watabe, D.1, Yokote, N.1, Kim, S.-W.2,
Mori, S.-I.2, Tanosaki, R.2, Heike, Y.2, Fukuda, T.2, Yamamoto, H.1
1National Cancer Center Hospital, Tokyo, Japan; 2National Cancer Cen-
ter Hospital, Tokyo, Japan
Background: The blood concentration of tacrolimus (TAC) is
known to be increased by concomitant administration of voricona-
zole (VRCZ) and itraconazole (ITCZ), azole anti-fungal agents.
We investigated changes in blood concentrations of TAC before
and after concomitant administration of VRCZ or ITCZ to exam-
ine the optimal timing for monitoring blood concentrations of
TAC.
Patients and Methods: We studied retrospectively patients who
underwent hematopoietic stem cell transplantation between April
2004 and June 2010 and started VRCZ or ITCZ use during TAC
administration. In a total of 34 patients receiving concomitant ad-
ministration of VRCZ (tablets, n 5 27; intravenous injection, n 5
7) and 11 receiving ITCZ (capsules [Cap], n 5 8; oral solution
[OS], n 5 3), the concentration/dose (C/D) ratio of TAC was ob-served from 10 days before through 35 days after the initiation of
VRCZ or ITCZ.
Results: In all VRCZ group patients, C/D ratios of TAC in-
creased after initiating VRCZ as compared with those before
(median, 293%; range, 131%-923%; P \ 0.001). Median time
to reach the peak C/D ratio was 8 days (range, 3-30 days).
When a loading dose was applied, the peak reached earlier (me-
dian, 6 days vs. 9.5 days; P 5 0.026). Then C/D ratios decreased
from peak (median, 50%; range, 23%-98%; P\ 0.001). In 10 pa-
tients in the ITCZ group, the C/D ratio increased after initiating
ITCZ as compared with those before (median, 267%; range,
141%-828%; P \ 0.001). Median time to reach the peak C/D
ratio was 19.5 days (range, 10-32 days). Patient who applied
a loading dose was none. The rates of C/D ratio increase differed
significantly between Cap and OS (median, 221% [range, 38%-
475%] vs. 513% [range, 440%-828%]; P 5 0.025) and times to
reach the peak C/D ratio were similar (median, 20 days vs. 19
days).
Conclusions: In the VRCZ group, since blood concentrations of
TAC transiently increased and then decreased, suggesting that care-
ful monitoring is required even after dose reduction. It is also sug-
gested that the optimal times for careful monitoring differ
depending on whether or not the loading dose is applied. In the
ITCZ group, the effects tended to appear after about 1 week. Signif-
icant increases in blood concentrations of TAC were observed in
patients who received ITCZ by OS.556
CORRELATION OF PATIENT CHARACTERISTICS INCLUDING AGE, OBE-
SITY, GENDER AND RACE ON THE METABOLISM OF BUSULFAN
Hutcherson, D.A.1, Mahoney, M.3, Ng, A.1, Wilson, N.M.1, Surati, M.1,
Shah, K.S.1, Flowers, C.R.2 1Emory Healthcare, Atlanta, GA; 2Emory
University School of Medicine, Atlanta, GA; 3University of Georgia,
Athens, GA
Background: Busulfan, in myeloablative doses, is commonly used in
conditioning regimens prior to hematopoietic stem cell transplanta-
tion (HSCT) and is associated with HSCT related toxicity including
hepatic veno-occlusive disease (VOD). Busulfan is predominantly
metabolized by conjugation with glutathione, both spontaneously
and by glutathione S-transferase catalysis. Busulfan dosing is com-
monly adjusted using therapeutic drug monitoring (TDM) to limit
toxicities. Whether patient characteristics such as race, age, obesity,
gender and prior chemotherapy can influence the metabolism of bu-
sulfan remains unclear.
Methods: A retrospective chart review was conducted in 302 pa-
tients receiving intravenous busulfan between April 26th, 2001 and
September 23rd, 2010. Data was obtained from an IRB approved bu-
sulfanTDMdatabase and included gender, race, age, weight, height,
BSA, BMI and elimination half-life obtained with the 1st dose of bu-
sulfan.
Results: Demographics included 172 males and 130 females, of
which there were 222 Caucasians, 50 African Americans and 30 pa-
tients of other races. The mean age was 43 with 113 patients
greater than 50 years old. Thirty patients weighed over 100 kg, 6
had a BMI \ 18.5, 175 had a BMI of 18.5 – 29.9 and 122 had
a BMI . / 5 30. The mean half-life for all patients was 188 min-
utes (ranging 108 to 640 minutes). For the 12 patients with a BSA
of 2.5 to 3.29, the mean half-life was 206 minutes (ranging 184 to
238 minutes). The half-lives for the small to large BMI groups were
186, 188 and 186 minutes. The half-life for females was 180 min-
utes vs. 194 minutes for males. The half-lives for Caucasians, Afri-
can Americans and other races were 187, 194 and 182 minutes,
respectively. Patients over 50 years old had a mean half-life of
189 minutes. For the entire group, wide variations in clearance
were observed with 11% of patients having a half-life . 230 and
8%\ 145 minutes. The maximum and minimum half-lives were
640 and 108 minutes.
Conclusion: Initial analysis of our data suggests that different dos-
ing strategies based on population specific parameters may not be
necessary. Pharmacists should continue to dose busulfan according
to their institutional guidelines but due to the wide variations
Poster Session II S353observed in busulfan metabolism, individualized dosage adjustments
should be made based on TDM.557
RETROSPECTIVE COMPARISON OF PHENYTOIN AND LEVETIRACETAM AS
SEIZURE PROPHYLAXIS WITH HIGH DOSE BUSULFAN DURING ALLOGE-
NEIC STEM CELL TRANSPLANT
Mathew, S.1, Harnicar, S.1, Adel, N.1, Papadopoulos, E.2 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan-
Kettering Cancer Center, New York, NY
Background: Busulfan is an alkylating agent commonly used in pre-
parative regimens for hematopoietic stem cell transplant (HSCT).
Early clinical trials, prior to the use of seizure prophylaxis, revealed
a high degree of neurotoxicity associated with myeloablative doses of
this agent. Phenytoin has been widely used as seizure prophylaxis
with busulfan. However, potential concerns with its use include
the length of time to achieve a therapeutic steady state, risk of hep-
atotoxicity, and drug-drug interactions with busulfan and other
agents used during conditioning. Alternatively, levetiracetam is
highly bioavailable in both oral and intravenous forms, with a short
half life it rapidly achieves steady state and is renally eliminated with
limited drug interactions. The main objective of this study was to
compare the incidence of seizures with phenytoin and levetiracetam.
Secondary objectives were to compare VOD incidence, assess busul-
fan and phenytoin pharmacokinetics, and toxicity of the prophylactic
agents.
Methods: All patients$ 18 years of age receiving busulfan in a pre-
parative regimen prior to HSCT between 6/1/08-6/30/09 were in-
cluded in this retrospective analysis. Patient information was
collected from the pharmacy database and electronic medical re-
cords. Data included age, disease, preparative regimen, type of trans-
plant, busulfan dose, busulfan AUC, survival status, incidence of
relapse, and hepatic panels.
Results: 54 patients were included in this analysis with 22 receiving
phenytoin and 32 receiving levetiracetam as seizure prophylaxis.
Phenytoin was dosed with a 1000 mg loading dose and 300 mg
daily maintenance dose. Levetiracetam was dosed at 500 mg twice
daily. Of the 54 patients there were no reports of seizures in either
group. There were also no reports of VOD in either group. Eleva-
tion in liver enzymes occurred in 3 (9%) patients who received lev-
etiracetam compared to 7 (32%) patients who received phenytoin.
A therapeutic steady state of phenytoin was achieved in 12 (55%)
patients. Twenty patients (63%) receiving levetiracetam needed bu-
sulfan dose adjustments based on pharmacokinetic analysis versus
11 (50%) receiving phenytoin. Rates of relapse were similar in
both groups.
Conclusion: Levetiracetam is a safe and effective alternative to phe-
nytoin for busulfan seizure prophylaxis. With low hepatoxicity, no
pharmacokinetic monitoring, and limited drug-drug interactions it
is an attractive option in the HSCT population.558
WEIGHT-BASED DOSING OF VALGANCICLOVIR IN PEDIATRIC HSCT RE-
CIPIENTS
Nguyen, N.-Y.1, Puebla, M.1, Krance, R.A.2 1Texas Children’s Hospital,
Houston, TX; 2Baylor College of Medicine, Houston, TX
Background: IV ganciclovir is the standard therapy to prevent CMV
infection in HSCT recipients at Texas Children’s Hospital. In 2001,
the FDA approved valganciclovir (VGC) for treatment of CMV ret-
initis in AIDS patients. This oral preparation increased the oral bio-
availability of ganciclovir from 5% to 60% and demonstrated a well
established safety profile. The oral route of administration avoids the
need for a central line and markedly decreases the added costs asso-
ciated with IV therapy. Unfortunately, data as to the efficacy of VGC
to preventCMV infection in pediatricHSCT recipients is limited. In
2004, our institution reported positive experience in liver transplant
patients using 15–18 mg/kg/dose. Encouraged by this result, the
HSCT program began using a similar dosing strategy for patients
unable to receive IV ganciclovir. This report evaluates the efficacyand safety of weight-based dosing of VGC for CMV prophylaxis
in pediatric HSCT recipients.
Methods: Thus far, we have evaluated thirty-two patients (2-20
years old) for this retrospective study. The inclusion criteria were: al-
logeneic HSCT recipients, CMV seropositive (donor and/or recip-
ient) prior to transplantation, received VGC $ 7 days. Exclusion
criteria were: ANC\ 500 and renal dysfunction. Efficacy was de-
fined as no incidence of CMV reactivation during therapy based
upon the development of CMV antigenemia or the presence of
CMV by quantitative PCR (qPCR). ANC served as a marker for
safety. The dosing was as follows: 15-18 mg/kg/dose (max 900 mg)
twice daily for 14 days, then once daily thereafter.
Results:Thedurationof therapy ranged 7days to2 years.The average
dose for patients\60 kgwas 15.2mg/kg/dose (8.2– 22.5mg/kg/dose.)
Patients$ 60 kg received a maximum 900 mg per dose. CMV reacti-
vationwas not observed in 30of 32 patients.Therapywas discontinued
in 4 patients due to declining ANC. Four patients required filgrastim
intermittently to maintain ANC. 500. Effect on ANC cannot be as-
sessed for one patient due to concurrent treatment with hydroxyurea.
Most importantly, no patient developed CMV pneumonitis.
Conclusion:Our data demonstrate that valganciclovir 15 – 18mg/kg/
dose is effective and safe as a CMV prophylactic regimen in pediatric
HSCT patients. However, frequent monitoring, including CMV
qPCR and hematologic profile, is necessary with VGC therapy.559
USE OF HEPATITIS B IMMUNE GLOBULIN AND ADEFOVIR IN A CORD
BLOOD TRANSPLANT RECIPIENT
DiMicco, M.G., Ahmed, T. Westchester Medical Center, Valhalla, NY
A 52-year old female with acute myelogenous leukemia in remis-
sion presented for a matched unrelated donor hematopoeitic stem
cell transplant, testing negative for Hepatitis B surface antigen.
The recipient underwent HPCT conditioning using the Slavin reg-
imen. The patient’s human leukocyte antigen (HLA) typingmatched
with a cord blood donation from a twin birth where the mother was
found to be Hepatitis B surface antigen positive; the HBsAg status of
the twin donors was unknown at the time of hematopoeitic stem cell
transplantation.
As a precaution against the recipient developing a Hepatitis B in-
fection, Hepatitis B Immune Globulin and Adefovir was adminis-
tered as chemoprophylaxis. Dosing of Hepatitis B Immune
Globulin was derived from the liver transplant literature. Hepatitis
B Immune Globulin 20,000 international units was given intrave-
nously on transplant day zero and repeated on transplant days 1
through 7. Additional doses were scheduled for every two weeks
to begin on transplant day +14. Adefovir 10 mg was ordered to
be administered by mouth daily beginning on transplant day nega-
tive 2.
On transplant day +19 the HBsAg status of the twin donors was
discovered to be negative.Hepatitis B chemoprophylaxis was discon-
tinued at that time with no additional doses administered to the re-
cipient.
Hepatitis B Immune Globulin is used in the liver transplantation
population to prevent hepatitis B virus recurrence inHBsAg-positive
recipients after transplantation. Adefovir is used to treat chronic hep-
atitis B infections.560
DECLINE IN BONE MINERAL DENSITY IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: IMPACT OF MYELOABLATIVE VERSUS
REDUCED INTENSITY CONDITIONING REGIMENS
McCullough, K.B.1, Burzynski, J.A.1, Hogan, W.J.2, Litzow, M.R.2,
Wolf, R.C.1, Wermers, R.A.3 1Mayo Clinic, Rochester, MN; 2Mayo
Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN
Background:Comparedwithmyeloablative (MA) regimens, reduced
intensity conditioning (RIC) regimens have shown a lower incidence
of some complications (veno-occlusive disease, pre-engraftment in-
fections, bronchiolitis obliterans); however, the incidence is similar
for others (chronic kidney disease, hypothyroidism). The incidence
of osteoporosis and osteopenia has not been compared.
